Mamantia, Rejane .
HRN: 23-58-04 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/21/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
08/21/2023
08/28/2023
IV
18mg
Q24h
Preterm, Potentially Septic
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes